The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations: Heat on Beat randomized phase II study.
 
Nobuhiko Seki
Speakers' Bureau - AstraZeneca Japan; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Chugai Pharma; Daiichi Sankyo; Johnson & Johnson/Janssen; Kyowa Kirin; Lilly; Merck; MSD Oncology; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca Japan (Inst); Boehringer Ingelheim; Chugai Pharma; Eisai; Lilly; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Shionogi; Taiho Pharmaceutical; Takeda
 
Kei Morikawa
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD; Takeda
Research Funding - DNA Chip Research Inc., Tokyo, Japan. (Inst)
 
Tomonori Makiguchi
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; GlaxoSmithKline; Lilly; Novartis Pharmaceuticals UK Ltd.
 
Shigeru Tanzawa
Honoraria - AstraZeneca; Chugai Pharma; MSD; Nippon Kayaku
Research Funding - AstraZeneca (Inst); Nippon Kayaku (Inst)
 
Tetsuo Shimizu
Honoraria - AstraZeneca; Chugai Pharma; MSD; Ono Yakuhin; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Lilly; Ono Yakuhin
 
Saori Takata
No Relationships to Disclose
 
Katsuhiko Naoki
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Meyers; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; MSD; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Parexel/CALYX (Inst); Taiho Pharmaceutical (Inst)
 
Yuichiro Takeda
Research Funding - Chugai Pharma
 
Tamotsu Ishizuka
Speakers' Bureau - AstraZeneca Japan
 
Yuko Oya
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Johnson & Johnson/Janssen; Lilly; MSD; Novartis; Taiho Pharmaceutical; Takeda; Tsumura & Co.
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Johnson & Johnson/Janssen
 
Tadashi Kohyama
No Relationships to Disclose
 
Kyoichi Kaira
Speakers' Bureau - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Ono Pharmaceutical
Research Funding - AstraZeneca Japan
 
Kazuma Kishi
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim
 
Satoshi Watanabe
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca; Nippon Kayaku
 
Takafumi Suda
Speakers' Bureau - Boehringer Ingelheim Seiyaku
Research Funding - Boehringer Ingelheim Seiyaku
 
Hiromichi Yamane
No Relationships to Disclose
 
Masashi Ishihara
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Taiho Pharmaceutical
 
Hiroshi Kagamu
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Lilly; MSD; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Meiji holdings (Inst)
Patents, Royalties, Other Intellectual Property - Biomarkers for predicting response to cancer therapy
 
Kenichi Yoshimura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Eisai; Lilly; Nihon-Shinyaku; Nihonkayaku; Novartis; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - BrightPath Biotheraputics; Nippon Shinyaku; Sysmex
 
Noriyuki Matsutani
No Relationships to Disclose